Shazam! Sanofi Pasteur strikes a chord with Fluzone audience

Share this article:
Shazam! Sanofi Pasteur strikes a chord with Fluzone audience
Shazam! Sanofi Pasteur strikes a chord with Fluzone audience

Sanofi Pasteur scored a pharma first this past winter by offering “Shazam” technology as a way for viewers to interact with TV commercials for its Fluzone Intradermal influenza vaccine—and to find out where they could get the new shot.

Shazam is a popular mobile app that detects what song is playing, subsequently directing users to iTunes where they can download it for the requisite few dollars. But by applying the same audio-detection technology to TV commercials, companies are able invite viewers to “Shazam” their ads and link to a mobile website for more information—rather like an audio QR code.  In this case, viewers were directed to a “locator” to find out where they could get a Fluzone shot.

According to Jennifer Havens, deputy director, consumer marketing at Sanofi Pasteur, who was addressing delegates at the DTC National Conference in Washington, DC, around 100,000 people used Shazam to request the locator.

The TV commercials, which featured brand mascot Henry the Porcupine, began running, naturally, at the start of flu season, spearheading a sophisticated and highly integrated marketing campaign for Fluzone—which boasts a 90% smaller needle than conventional flu shots.

Other components included a PR campaign featuring NCIS: Los Angeles star Chris O'Donnell, who appeared as a Fluzone spokesperson on a number of high-profile TV shows, and the Coop de Quill VacciNation Tour, which visited five markets across the US.

According to Michael Szumera, director of PR and communications US at Sanofi Pasteur, the campaign reached more than 161 million consumers in total, with an awareness rate of 45%.

The TV spots were aired 2,139 times, including prime-time spots on the three national networks, garnering around one billion impressions. The website notched up more than 700,000 visits, with half of these visiting the locator. Digital advertising achieved 100 million impressions. Print ads in nine magazines yielded 127 million impressions. Around 130,000 brochures and 8,000 posters were distributed. Meanwhile the PR campaign achieved one billion impressions, with 412 stories generated in print, 45 on TV, 1,092 on radio and 1,733 online.

Szumera said that 40% of consumers exposed to the campaign elements now felt there was a better flu shot experience available. Furthermore, consumers initiated 60% of conversations with healthcare professionals about the flu. And 46% of these said the conversations were prompted by the TV commercial, while another 57% also saw it in the news.

In other Sanofi Pasteur news, the company last week awarded the US PR accounts for its influenza and meningitis businesses to W2O Group and Chandler Chicco's Biosector 2 unit, according to a story in PRWeek. Collectively, the work is believed to be worth around $4 million.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...